Aktis Oncology (NASDAQ:AKTS) Shares Up 5.8% – What’s Next?

Shares of Aktis Oncology (NASDAQ:AKTS) shot up 5.8% during mid-day trading on Tuesday . The stock traded as high as $26.10 and last traded at $26.23. Approximately 34,422 shares were traded during mid-day trading, a decline of 89% from the average session volume of 304,971 shares. The stock had previously closed at $24.79.

Analysts Set New Price Targets

A number of brokerages have recently commented on AKTS. William Blair assumed coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating on the stock. Raymond James Financial started coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, June 9th. Finally, HC Wainwright upped their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Up 8.6%

The stock has a 50 day moving average of $19.97.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million during the quarter. On average, analysts expect that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.